Nexplanon(®): what Implanon(®) did next.

©FSRH J Fam Plann Reprod Health Care 2010: 36(4) Introduction Etonogestrel (ENG) contraceptive subdermal implants [Implanon®, Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD), UK] have been available for more than 10 years in the UK. Over 180 000 implants are now fitted each year, with approximately 6 million women using this method worldwide (MSD, data on file, July 2010). The Department of Health1 and National Institute for Health and Clinical Excellence (NICE)2 have encouraged use of the ENG implant by providing additional funds to improve access to contraceptive methods through primary care trust and strategic health authority initiatives along with providing clear, concise information in a clinical guideline published in October 2005.2